Dr. Jasjit S. Walia
Dr. Walia is actively involved in research and training of medical students, residents, fellows and other physicians. His patients appreciate his considerate bedside manners and the human touch that he brings to their overall care. He believes in communicating with patients and their family members on a personal level, which has earned him the loyalty of his patients. He is fluent in English, Indian languages and speaks Spanish as well.
Medical Education and Training
Residency and Fellowship
- July 1998 – June 2001 Fellowship in Cardiology at Wayne State University, Detroit, Michigan
- Dec. 1998 – June 2001 -MBA, Wayne State University Detroit, MI
- July 1997 – June 1998 Hospitalist/Intensivist, Richmond Heights Hospital, Ohio
- July 1994 – June 1997 – Residency in Internal Medicine. UMDNJ/ New Jersey Medical School Newark, NJ.
- Chief Resident from July 1996-June 1997 during the residency.
- June 1993 – June 1994 – Internship in Family Practice Reading Hospital and Medical Center Reading, PA.
- July 1986 – Dec. 1991 – M.B.B.S Government Medical College Punjab, India Residency and
Licensure and Board Certification
Licensed in New Jersey Board Certified by the ABIM in Cardiovascular diseases and Internal Medicine. Board Certified in Nuclear Cardiology. Fellow of the American College of Cardiology.
Hospital Appointments
Trinitas Hospital, 225 Williamson Street, Elizabeth, NJ
Newark Beth Israel Medical Center, Newark, NJ
Academic and Administrative Appointments-
Clinical faculty- University Hospital/Rutgers Medical School, Newark, NJ.
Professional Memberships – Fellow of American College of Cardiology.
Research and Publications
1. Aortic rupture: comparison of three imaging modalities Journal Emergency Radiology Issue Volume 13, Number 1 / September, 2006 Category Original article DOI 10.1007/s10140-006-0497-5 Pages 31-33 Online Date Thursday, June 29, 2006 Original article Aortic rupture: comparison of three imaging modalities Monica Sanchez-Ross1, Ather Anis1, Jasjit Walia1, Preet Randhawa1, Barry C. Esrig2, Michael C. Banker2, Corey Eber3, Pierre Maldjian3, Marc Klapholz1 and Muhamed Saric1, 4 Received: 1 July 2005 Accepted: 4 May 2006 Published online: 29 June 2006
2. Cardionet Trial has been published by the Journal of Cardiac Electrophysiology. The Diagnosis of Cardiac Arrhythmias: A Prospective Multi-Center Randomized Study Comparing Mobile Cardiac Outpatient Telemetry versus Standard Loop Event Monitoring Steven A. Rothman, MD* James C. Laughlin, MD* Jonathan Seltzer, MD* Jasjit S. Walia, MBBS Rakesh I. Baman, MD! Samer Y. Siouffi, MD§ Robert M. Sangrigoli, MD Peter R. Kowey, MD*
3. Investigator for -A-HeFT( African-American Heart Failure Trial)- Placebo-Controlled Trial of BiDil Added to Standard Therapy in African-American Patients with Heart Failure- site 238 Original article published in the New England Journal of Medicine. Volume 351:2049-2057 November 11, 2004 Number 20 Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure African-American Heart Failure Trial
4. DORADO-AC- Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension. Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or more Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo
5. ACT – START DATE: 5/2005 The purpose of this registry to produce a prospective, outcome-oriented registry of all patients implanted with an SJM ICD. The secondary aim of the registry is to evaluate the programming and application of advanced features on ICD therapy in patients with SJM ICD’s.
6. ULTRA- START DATE: 7/2005 The primary objective of the Ultra study is to demonstrate a difference in average ventricular voltage output over time for patients randomized to Automatic Capture ON versus patients randomized to Automatic Capture OFF. The primary analysis for this objective will be based on the difference between the group in the average ventricular voltage output over the course of follow-up.
7. OMNI- START DATE: 9/2005 The Medtronic OMNI Study is a post-market observational study conducted in the United States (US). The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implatable Cardioverter Defibrillator (ICD)
8. MEDTRONIC P3- START DATE: 2/5005 The objective of the P3 study are to characterize the relationship between subject clinical profile at implant. Also to characterize clinical outcome and clinical management practice patterns.
9. ROCKET- AF- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.
N Engl J Med 2011; 365:883-891September 8, 2011DOI: 10.1056/NEJMoa1009638
10. REVEAL-The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the risk of coronary death, myocardial infarction (MI) or coronary revascularization (collectively known as major coronary events) in patients with circulatory problems who have their Low-density Lipoprotein (LDL) cholesterol level treated with a statin.
11. PEGASUS- Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)
12. Pfizer – global Phase 3 program to evaluate the efficacy and safety of bococizumab (the proposed generic name for RN316/PF-04950615), a subcutaneously administered monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9).
19. ETHNICITY- The ACS Ethnicity Platelet Function Study. This study is being done to assess the effects of the CTP inhibitor on the function of your platelets (cells within your blood that are involved in the formation of blood clots) and to assess whether you have responded to the ticagrelor well enough to prevent the formation of blood clots within the stent or site in which angioplasty was performed.
20. ALMICAD –Lipid management in CAD patients, 2000
21. ARRIVE : CHD events, 2007
22. Orbit AF: Atrial fibrillation, 2010
23. Elixa: Diabetes in Coronary artery disease
24. SUMMIT: COPD, 2013
25. CARMALINA: Diabetic Study, 2013
26. Orbit 11: Atrial fibrillation, 2013
27. ICON study: acute coronary syndrome, 2013